Albert David Limited (NSE:ALBERTDAVD)
705.90
-0.40 (-0.06%)
May 22, 2026, 3:29 PM IST
Albert David Revenue
In the fiscal year ending March 31, 2026, Albert David had annual revenue of 3.34B INR, down -3.52%. Albert David had revenue of 858.63M in the quarter ending March 31, 2026, with 14.65% growth.
Revenue
3.34B
Revenue Growth
-3.52%
P/S Ratio
1.20
Revenue / Employee
1.85M
Employees
1,805
Market Cap
4.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.34B | -121.70M | -3.52% |
| Mar 31, 2025 | 3.46B | -166.94M | -4.61% |
| Mar 31, 2024 | 3.62B | 208.97M | 6.12% |
| Mar 31, 2023 | 3.42B | 280.53M | 8.95% |
| Mar 31, 2022 | 3.14B | 660.62M | 26.70% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nectar Lifesciences | 16.70B |
| Ind-Swift Laboratories | 5.94B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.96B |
| Jagsonpal Pharmaceuticals | 2.87B |
| Balaxi Pharmaceuticals | 2.76B |
| Valiant Laboratories | 2.37B |
| Bafna Pharmaceuticals | 1.47B |